Payment overview · 2025
General Payments
$129.40
7 reported records · 4 companies
Healthcare provider profile · identity verified
Jesse B Scott, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLAXTON, GA · NPI 1235213158
Verified facts
What the public records show
CMS Open Payments records show Jesse B Scott, MD received $129.40 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 55.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.23 | 55.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.01 | 17.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.17 | 14.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.99 | 12.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $129.40 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 189 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 166 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
189 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
189 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 685 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 564 | 88 |
| Losartan Potassium | Losartan Potassium | 535 | 86 |
| Omeprazole | Omeprazole | 505 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 93 |
| Potassium Chloride | Potassium Chloride | 488 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 396 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 378 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 373 | 53 |
| Furosemide | Furosemide | 355 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 282 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 61 |
| Gabapentin | Gabapentin | 266 | 47 |
| Lisinopril | Lisinopril | 255 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 48 |
| Simvastatin | Simvastatin | 247 | 50 |
| Eliquis | Apixaban | 232 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 32 |
| Carvedilol | Carvedilol | 217 | 44 |
| Allopurinol | Allopurinol | 214 | 31 |
| Metformin Hcl Er | Metformin Hcl | 190 | 36 |
| Jardiance | Empagliflozin | 189 | 27 |
| Metformin Hcl | Metformin Hcl | 188 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 183 | 37 |
| Benazepril Hcl | Benazepril Hcl | 179 | 34 |
| Alprazolam | Alprazolam | 176 | 35 |
| Ozempic | Semaglutide | 166 | 22 |
| Tramadol Hcl | Tramadol Hcl | 166 | 36 |
| Famotidine | Famotidine | 165 | 35 |
| Clonazepam | Clonazepam | 161 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 42 |
| Finasteride | Finasteride | 157 | 24 |
| Celecoxib | Celecoxib | 153 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 27 |
| Meloxicam | Meloxicam | 143 | 26 |
| Temazepam | Temazepam | 133 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 130 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 36 |
| Trazodone Hcl | Trazodone Hcl | 109 | 13 |
| Xarelto | Rivaroxaban | 106 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 103 | 57 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 23 |
| Montelukast Sodium | Montelukast Sodium | 100 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 99 | 14 |
| Lorazepam | Lorazepam | 98 | 22 |
| Pregabalin | Pregabalin | 98 | 19 |
| Sertraline Hcl | Sertraline Hcl | 98 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 97 | 13 |
| Alendronate Sodium | Alendronate Sodium | 94 | 17 |
| Synthroid | Levothyroxine Sodium | 92 | 15 |
| Prednisone | Prednisone | 90 | 36 |
| Bupropion Xl | Bupropion Hcl | 87 | suppressed |
| Glimepiride | Glimepiride | 87 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 14 |
| Chlorthalidone | Chlorthalidone | 81 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 19 |
| Fluconazole | Fluconazole | 77 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 15 |
| Ondansetron Odt | Ondansetron | 74 | 35 |
| Ezetimibe | Ezetimibe | 70 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 68 | 15 |
| Glipizide Er | Glipizide | 66 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 11 |
| Atenolol | Atenolol | 63 | 17 |
| Colesevelam Hcl | Colesevelam Hcl | 62 | suppressed |
| Januvia | Sitagliptin Phosphate | 60 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 58 | suppressed |
| Diazepam | Diazepam | 55 | 11 |
| Lovastatin | Lovastatin | 55 | 11 |
| Digoxin | Digoxin | 53 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 51 | suppressed |
| Estradiol | Estradiol | 49 | 11 |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 23 |
| Colchicine | Colchicine | 45 | 17 |
| Donepezil Hcl | Donepezil Hcl | 45 | 12 |
| Felodipine Er | Felodipine | 45 | suppressed |
| Valsartan | Valsartan | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 42 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 39 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 22 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Levemir Flexpen | Insulin Detemir | 35 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 24 |
| Eszopiclone | Eszopiclone | 33 | 12 |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 32 | 29 |
| Klor-Con M20 | Potassium Chloride | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Nystatin | Nystatin | 31 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 31 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 25 |
| Mupirocin | Mupirocin | 30 | 18 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 18 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.40 · 7 records | Novo Nordisk Inc | Cologuard Collection Kit, JARDIANCE, MOUNJARO, Ozempic, Rybelsus, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error